Literature DB >> 27867996

Towards a cure for Fibrodysplasia ossificans progressiva.

Gonzalo Sanchez-Duffhues1, David J J de Gorter2, Peter Ten Dijke1.   

Abstract

Entities:  

Year:  2016        PMID： 27867996      PMCID： PMC5104602          DOI： 10.21037/atm.2016.10.62

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.

Authors:  J Kaplan; F S Kaplan; E M Shore
Journal:  Gene Ther       Date:  2011-10-20       Impact factor: 5.250

2.  Development of an ALK2-biased BMP type I receptor kinase inhibitor.

Authors:  Agustin H Mohedas; Xuechao Xing; Kelli A Armstrong; Alex N Bullock; Gregory D Cuny; Paul B Yu
Journal:  ACS Chem Biol       Date:  2013-04-30       Impact factor: 5.100

3.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

4.  An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.

Authors:  Salin A Chakkalakal; Deyu Zhang; Andria L Culbert; Michael R Convente; Robert J Caron; Alexander C Wright; Andrew D A Maidment; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

Review 5.  BMP signalling in skeletal development, disease and repair.

Authors:  Valerie S Salazar; Laura W Gamer; Vicki Rosen
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

6.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

7.  Characterization of type I receptors for transforming growth factor-beta and activin.

Authors:  P ten Dijke; H Yamashita; H Ichijo; P Franzén; M Laiho; K Miyazono; C H Heldin
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

8.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

9.  The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.

Authors:  Emilie Barruet; Blanca M Morales; Wint Lwin; Mark P White; Christina V Theodoris; Hannah Kim; Ashley Urrutia; Sarah Anne Wong; Deepak Srivastava; Edward C Hsiao
Journal:  Stem Cell Res Ther       Date:  2016-08-17       Impact factor: 6.832

10.  The role of the 3'UTR region in the regulation of the ACVR1/Alk-2 gene expression.

Authors:  Marzia Mura; Serena Cappato; Francesca Giacopelli; Roberto Ravazzolo; Renata Bocciardi
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240
View more
  4 in total

1.  Atypical Presentation of Fibrodysplasia Ossificans Progressiva: A Case Report and Review of Literature.

Authors:  Vivek Tiwari; Prateek Behera; Radha Sarawagi; Babu Mohammed Rafi; Saurabh Sahu; Hemanth Raj; Manish Rajpoot
Journal:  Cureus       Date:  2018-07-10

Review 2.  The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.

Authors:  Hui Lin; Fuli Shi; Jiayu Gao; Ping Hua
Journal:  Biosci Rep       Date:  2019-08-02       Impact factor: 3.840

3.  Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.

Authors:  Gonzalo Sánchez-Duffhues; Eleanor Williams; Pascal Benderitter; Valeria Orlova; Michiel van Wijhe; Amaya Garcia de Vinuesa; Georgina Kerr; Josselin Caradec; Kirsten Lodder; Hetty C de Boer; Marie-José Goumans; Elisabeth M W Eekhoff; Antonio Morales-Piga; Javier Bachiller-Corral; Pieter Koolwijk; Alex N Bullock; Jan Hoflack; Peter Ten Dijke
Journal:  JBMR Plus       Date:  2019-10-07

Review 4.  Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.

Authors:  Arun-Kumar Kaliya-Perumal; Tom J Carney; Philip W Ingham
Journal:  Dis Model Mech       Date:  2020-09-21       Impact factor: 5.758
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.